Edgewise Therapeutics Inc
EWTX24.900USD
-0.070-0.28%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
2.63BMarket Cap
LossP/E TTM
More Details of Edgewise Therapeutics Inc Company
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
Edgewise Therapeutics Inc Info
Ticker SymbolEWTX
Company nameEdgewise Therapeutics Inc
IPO dateMar 26, 2021
CEOKoch (Kevin)
Number of employees110
Security typeOrdinary Share
Fiscal year-endMar 26
Address1715 38Th St
CityBOULDER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code80301
Phone17202627002
Websitehttps://edgewisetx.com/
Ticker SymbolEWTX
IPO dateMar 26, 2021
CEOKoch (Kevin)
Company Executives of Edgewise Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Kevin Koch, Ph.D.
Dr. Kevin Koch, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
369.40K
+9996.00%
Dr. Joanne M. Donovan, M.D., Ph.D.
Dr. Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.41K
+2919.00%
Dr. Jonathan C. Fox, M.D., Ph.D.
Dr. Jonathan C. Fox, M.D., Ph.D.
Independent Director
Independent Director
23.70K
+10700.00%
Dr. Behrad Derakhshan, Ph.D.
Dr. Behrad Derakhshan, Ph.D.
Chief Operating Officer
Chief Operating Officer
23.64K
+3290.00%
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
19.82K
--
Dr. Jonathan D. (Jon) Root, M.D.
Dr. Jonathan D. (Jon) Root, M.D.
Independent Director
Independent Director
15.63K
--
Mr. John R. Moore
Mr. John R. Moore
General Counsel
General Counsel
5.03K
+3683.00%
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
--
--
Dr. Alan Russell, Ph.D.
Dr. Alan Russell, Ph.D.
Chief Scientific Officer, Director, Co-Founder
Chief Scientific Officer, Director, Co-Founder
--
--
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Kevin Koch, Ph.D.
Dr. Kevin Koch, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
369.40K
+9996.00%
Dr. Joanne M. Donovan, M.D., Ph.D.
Dr. Joanne M. Donovan, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.41K
+2919.00%
Dr. Jonathan C. Fox, M.D., Ph.D.
Dr. Jonathan C. Fox, M.D., Ph.D.
Independent Director
Independent Director
23.70K
+10700.00%
Dr. Behrad Derakhshan, Ph.D.
Dr. Behrad Derakhshan, Ph.D.
Chief Operating Officer
Chief Operating Officer
23.64K
+3290.00%
Dr. Badreddin Edris, Ph.D.
Dr. Badreddin Edris, Ph.D.
Independent Director, Co-Founder
Independent Director, Co-Founder
19.82K
--
Dr. Jonathan D. (Jon) Root, M.D.
Dr. Jonathan D. (Jon) Root, M.D.
Independent Director
Independent Director
15.63K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
14.66%
RA Capital Management, LP
9.85%
Baker Bros. Advisors LP
6.90%
Paradigm BioCapital Advisors LP
5.83%
Novo Holdings A/S
5.05%
Other
57.71%
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
14.66%
RA Capital Management, LP
9.85%
Baker Bros. Advisors LP
6.90%
Paradigm BioCapital Advisors LP
5.83%
Novo Holdings A/S
5.05%
Other
57.71%
Shareholder Types
Shareholders
Proportion
Hedge Fund
28.84%
Investment Advisor
22.58%
Investment Advisor/Hedge Fund
19.17%
Private Equity
18.24%
Venture Capital
16.37%
Research Firm
1.55%
Individual Investor
0.54%
Pension Fund
0.21%
Bank and Trust
0.17%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
398
113.51M
107.21%
-19.75M
2025Q3
392
119.88M
108.70%
-25.05K
2025Q2
397
119.92M
109.42%
+13.50M
2025Q1
381
106.67M
114.89%
-2.71M
2024Q4
360
100.40M
111.45%
-3.06M
2024Q3
330
102.86M
113.45%
-343.49K
2024Q2
288
102.77M
111.98%
+3.64M
2024Q1
262
99.10M
100.16%
+5.54M
2023Q4
235
80.75M
106.84%
+11.50M
2023Q3
209
69.33M
124.25%
-915.96K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
OrbiMed Advisors, LLC
15.52M
14.66%
--
--
Sep 30, 2025
RA Capital Management, LP
10.43M
9.85%
+525.80K
+5.31%
Sep 30, 2025
Baker Bros. Advisors LP
7.31M
6.9%
--
--
Sep 30, 2025
Paradigm BioCapital Advisors LP
6.17M
5.83%
+27.79K
+0.45%
Sep 30, 2025
Novo Holdings A/S
5.35M
5.05%
--
--
Sep 30, 2025
Braidwell LP
5.21M
4.92%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.08M
4.8%
-380.98K
-6.98%
Sep 30, 2025
Janus Henderson Investors
4.98M
4.7%
-524.02K
-9.52%
Sep 30, 2025
The Vanguard Group, Inc.
4.79M
4.53%
-37.56K
-0.78%
Sep 30, 2025
Cormorant Asset Management, LP
4.01M
3.79%
-241.99K
-5.69%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
3.27%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.09%
State Street SPDR S&P Pharmaceuticals ETF
1.71%
ALPS Medical Breakthroughs ETF
0.81%
Virtus LifeSci Biotech Clinical Trials ETF
0.8%
First Trust Multi-Manager Small Cap Opportunities ETF
0.55%
iShares U.S. Pharmaceuticals ETF
0.5%
ProShares Ultra Nasdaq Biotechnology
0.33%
Optimize Strategy Index ETF
0.26%
iShares Health Innovation Active ETF
0.25%
View more
iShares Neuroscience and Healthcare ETF
Proportion3.27%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.09%
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.71%
ALPS Medical Breakthroughs ETF
Proportion0.81%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.8%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.55%
iShares U.S. Pharmaceuticals ETF
Proportion0.5%
ProShares Ultra Nasdaq Biotechnology
Proportion0.33%
Optimize Strategy Index ETF
Proportion0.26%
iShares Health Innovation Active ETF
Proportion0.25%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Edgewise Therapeutics Inc?
The top five shareholders of Edgewise Therapeutics Inc are:
OrbiMed Advisors, LLC holds 15.52M shares, accounting for 14.66% of the total shares.
RA Capital Management, LP holds 10.43M shares, accounting for 9.85% of the total shares.
Baker Bros. Advisors LP holds 7.31M shares, accounting for 6.90% of the total shares.
Paradigm BioCapital Advisors LP holds 6.17M shares, accounting for 5.83% of the total shares.
Novo Holdings A/S holds 5.35M shares, accounting for 5.05% of the total shares.
OrbiMed Advisors, LLC holds 15.52M shares, accounting for 14.66% of the total shares.
RA Capital Management, LP holds 10.43M shares, accounting for 9.85% of the total shares.
Baker Bros. Advisors LP holds 7.31M shares, accounting for 6.90% of the total shares.
Paradigm BioCapital Advisors LP holds 6.17M shares, accounting for 5.83% of the total shares.
Novo Holdings A/S holds 5.35M shares, accounting for 5.05% of the total shares.
What are the top three shareholder types of Edgewise Therapeutics Inc?
The top three shareholder types of Edgewise Therapeutics Inc are:
OrbiMed Advisors, LLC
RA Capital Management, LP
Baker Bros. Advisors LP
OrbiMed Advisors, LLC
RA Capital Management, LP
Baker Bros. Advisors LP
How many institutions hold shares of Edgewise Therapeutics Inc (EWTX)?
As of 2025Q4, 398 institutions hold shares of Edgewise Therapeutics Inc, with a combined market value of approximately 113.51M, accounting for 107.21% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.49%.
What is the biggest source of revenue for Edgewise Therapeutics Inc?
In --, the -- business generated the highest revenue for Edgewise Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
